Royalty Pharma (RPRX) Expected to Announce Earnings on Thursday

Royalty Pharma (NASDAQ:RPRX) is projected to announce its earnings results before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of $1.09 per share and revenue of $743.60 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 50.53% and a return on equity of 24.65%. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Royalty Pharma Stock Up 1.5 %

Shares of NASDAQ RPRX opened at $32.85 on Wednesday. The company has a 50 day simple moving average of $28.70 and a 200 day simple moving average of $27.82. The firm has a market cap of $19.35 billion, a PE ratio of 17.02 and a beta of 0.49. Royalty Pharma has a 1 year low of $24.05 and a 1 year high of $32.89. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date is Friday, February 21st. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on RPRX shares. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Citigroup lowered their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, October 25th. Finally, StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and a consensus target price of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.